Facebook
X
LinkedIn
Forward
Establishing Multidisciplinary Clinical Pathways for Proactive, Individualized Treatment of Inflammatory Bowel Disease
Colchester, VT US
November 25, 2025
Vermont Gastroenterology
Despite advances and the availability of different therapies for the treatment of IBD, many patients never achieve or maintain remission and/or are dissatisfied with aspects of their therapy. Selecting, intensifying, sequencing, or combining therapies in IBD can be challenging for clinicians, especially considering the number of novel targeted therapies available. A decade ago, the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative advanced the care paradigm through promotion of treat-to-target (T2T) strategies and most recently, updated its recommendations to include time-dependent treatment targets.
Moreover, with continued therapeutic advances, the FDA now requires IBD clinical trials to use both endoscopic endpoints to assess mucosal inflammation as well as patient-reported outcomes (PROs), which encompass a patient's subjective experience of their symptoms, quality of life, and disease impact. Inclusion of PROs in therapeutic decision making offers a more comprehensive picture beyond just objective clinical measures, allowing clinicians to tailor treatment plans based on the patient's individual perspective and priorities.
However, gastroenterologists report a myriad of barriers in adopting T2T strategies in routine clinical practice. Some are resource driven, with greater constraints in monitoring experienced by smaller clinical practices, but others are an absence of risk factors for patient stratification or prognostic criteria to inform treatment selection.
As the prevalence of IBD continues to increase, gastroenterology teams must continually assess and adapt to evolving therapeutic strategies to ensure proactive, targeted, and patient-centric treatment to improve outcomes. To facilitate that exercise, leaders within gastroenterology settings will use expert-developed content to facilitate a 1-hour learning and action planning program with their multidisciplinary clinical team to review and enhance their practices and processes for individualized treatment of IBD considerate of their resources and staffing.
Educational Partner: Academy for Continued Healthcare Learning (ACHL)
Commercial Support: Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Takeda Pharmaceuticals U.S.A., Inc.
Commercial Support: Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Takeda Pharmaceuticals U.S.A., Inc.
Target Audience
This activity is intended for gastroenterologists, gastroenterology-focused advanced practice providers, internists, clinical pharmacists, gastroenterology nurses, and other members of the multidisciplinary care team.
Learning Objectives
Upon completion of this activity, learners will be able to:
- Apply proactive treat-to-target strategies to facilitate management of IBD and improve patient outcomes;
- Use and interpret available and emerging biomarkers in clinical practice to facilitate use of precision medicine in the management of IBD;
- Evaluate efficacy and safety data of emerging therapies with novel mechanisms of action for the management of IBD.
You may also be interested in
Vermont Gastroenterology
875 Roosevelt Hwy
Colchester, VT
05446
United States
WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website!
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org/.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO FACULTY
Chair
Russell D. Cohen, MD, FACG, AGAF
Professor of Medicine, Pritzker School of Medicine
Co-Director, Digestive Diseases Center
Clinical Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
Russell D. Cohen, MD, FACG, AGAF
Professor of Medicine, Pritzker School of Medicine
Co-Director, Digestive Diseases Center
Clinical Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
Faculty
David Choi, PharmD, BCACP
Clinical Pharmacy Specialist – Gastroenterology
Associate Director Inflammatory Bowel Disease Center
David Choi, PharmD, BCACP
Clinical Pharmacy Specialist – Gastroenterology
Associate Director Inflammatory Bowel Disease Center
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
REGISTRATION: Registration is not open to the public.
For questions or more information, visit the ACHL website or click the button below!
For questions or more information, visit the ACHL website or click the button below!
Please login or create an account to proceed.